We are so excited to welcome Commonwealth Diagnostics International, Inc. (CDI) to Rupa Health! We had a great conversation with Drew Connors, VP of Operations at CDI, to learn more about the company and the tests they offer.
Introducing Commonwealth Diagnostics International (CDI)!
Hi, Drew! I am excited to chat with you today. To start, can you tell me how CDI came to be?
At 24, Craig Strasnick started his first company, Commonwealth Laboratories LLC, with just three employees. After successfully growing the company's workforce to more than 100 employees in their Massachusetts facility, with operations expanded throughout the U.S. and abroad, he sold the company to one of the largest pharmaceutical companies in 2015. He then co-founded Commonwealth Diagnostics International (CDI) to continue his entrepreneurial journey to improve diagnostics and treatment of patients suffering from gastrointestinal disorders. Since its inception in the U.S., CDI has successfully expanded its diagnostic services internationally with strategic partnerships and now works with some of the preeminent health systems in the world.
That’s fantastic! Can you tell me a little more about the focus of CDI?
CDI helps providers identify and diagnose common sources of digestive distress and functional gastrointestinal ailments with our non-invasive and cost-effective portfolio of at-home functional GI diagnostic products and solutions. Our tests help diagnose many gastrointestinal disorders, including SIBO, IMO, IBS, and carbohydrate malabsorption.
Amazing! What are CDI’s most commonly ordered tests?
The most commonly ordered tests are the SIBO/IMO Lactulose (or Glucose) Breath Test and the Lactose Malabsorption Breath Test. These tests aid in the diagnosis of small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth (IMO), and lactose malabsorption.
What kind of technology do you use to analyze these tests?
CDI operates out of our state-of-the-art CLIA-certified laboratory located in Salem, Massachusetts. Our functional GI diagnostic lab ensures sample intake efficiency, analytical accuracy, quality assurance, and expedited result turnaround time. Working with one of the premier manufacturers in the gas chromatography (GC) market, CDI has developed an optimal combination of custom component parts, the use of a two-detector system, and specific method parameters to make our instruments more accurate, precise, and sensitive in detecting all three gases of interest in breath testing: hydrogen (H2), methane (CH4), and carbon dioxide (CO2).
Incredible! Is there anything else you would like to share about CDI?
CDI’s goal has always been to make a change and create something of value for millions of people suffering from gastrointestinal ailments. Our diagnostic technologies have impacted thousands of healthcare providers and millions of patients' quality of life. CDI strives to bring to market the necessary tools to give every provider the clinical data they and their patients desire. We are committed to delivering our services in the most convenient, customer-centric, and effective manner possible.
Wow! What a great way to end the conversation. We appreciate you taking the time to speak with us, and we look forward to growing our partnership with CDI.
%201.svg){kind=logo}
